Filing Flows › Tarsus Pharmaceuticals (TARS) › Q2 2026 › vs Q1 2026
Tarsus Pharmaceuticals (TARS) Q2 2026 vs Q1 2026 (quarter over quarter)
Tarsus Pharmaceuticals's revenue rose $11.9M (+7%) from $162M in Q1 2026 to $174M in Q2 2026.
Tarsus Pharmaceuticals, Q2 2026: revenue $174M (+69% year over year), operating margin -11.4%, net loss $18.6M, operating cash flow $61.2M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 32.9% | -18.8% | +51.7 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $174M | $162M | $11.9M | +7% |
| Other income, net | $4.1M | $1.5M | $2.6M | +170% |
| Net loss | $18.6M | $7.0M | $11.6M | +166% |
| Costs & expenses | $197M | $171M | $26.0M | +15% |
| Operating costs | $194M | $168M | $25.6M | +15% |
| Income tax | $2.7M | $2.4M | $364K | +15% |
| Cost of revenue | $12.1M | $9.4M | $2.7M | +29% |
| Research & development | $31.0M | $22.4M | $8.7M | +39% |
| SG&A | $151M | $136M | $14.3M | +10% |
| Operating cash sources | $79.8M | −$17.7M | $97.5M | — |
| Depreciation & amortization | $1.0M | $437K | $563K | +129% |
| Share-based compensation | $13.3M | $12.0M | $1.3M | +11% |
| Working capital & other | $65.5M | −$30.1M | $95.6M | — |
| Net loss absorbed | $18.6M | $7.0M | $11.6M | +166% |
| Operating cash flow | $61.2M | −$24.7M | $85.9M | — |
| Free cash flow (OCF − capex) | $57.2M | −$30.5M | $87.6M | — |
| Capital expenditures | $4.1M | $5.8M | −$1.7M | -30% |
Questions
How much did Tarsus Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Tarsus Pharmaceuticals's revenue rose $11.9M (+7%) from $162M in Q1 2026 to $174M in Q2 2026.